Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : LastShadow's Position Trading -- Ignore unavailable to you. Want to Upgrade?

To: LastShadow who wrote (29528)	1/20/2000 5:52:00 PM
From: AlienTech	Respond to of 43080

All the old guys must be out in force these days.. MOUNTAIN VIEW, Calif., Jan 20 (Reuters) - Vivus Inc ., developer of drugs to treat sexual dysfunction, on Thursday said it expects fourth-quarter earnings of between 40 and 42 cents per share, significantly above Wall Street's projections. Analysts had expected the company to lose 5 cents per share, according to First Call/Thomson Financial. The increase is primarily due to additional revenues recorded as part of the resolution of financial obligations related to the return to Vivus of marketing and distribution rights for MUSE (alprostadil) -- a treatment for impotence -- from Swedish drug group AstraZeneca Plc, The company is expected to report quarterly and year-end financial results on January 26. ((Ilaina Jonas, New York Newsdesk, 212-859-1676)) REUTERS Rtr 06:36 01-20-00